newsfilter
← Latest News
GlobeNewswire·

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

For investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the